MAVS sirna

MAVS siRNA (Human)

Cat. Num. AAA8208770

• Gene Names: MAVS; IPS1; VISA; IPS-1; CARDIF
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MAVS; MAVS siRNA (Human); IPS1; KIAA1271; VISA; Mitochondrial antiviral-signaling protein; CARD adapter inducing interferon beta; Cardif; Interferon beta promoter stimulator protein 1; IPS-1; Putative NF-kappa-B-activating protein 031N; Virus-induced-signaling adapter; MAVS sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: MAVS siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 399

• Applicable Applications for MAVS sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MAVS gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MAVS sirna

siRNA to inhibit MAVS expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 330688443
• NCBI GeneID: 57506
• NCBI Accession #: NP_001193420.1
• NCBI GenBank Nucleotide #: NM_001206491.1
• UniProt Accession #: Q7Z434; Q2HWT5; Q3I0Y2; Q5T7I6; Q86VY7; Q9H1H3; Q9H4Y1; A8K6X0; B2BD33; B2BD34; F5H6C8; M1P2Z0
• Molecular Weight: 15,012 Da
• NCBI Official Full Name: mitochondrial antiviral-signaling protein isoform 2
• NCBI Official Synonym Full Names: mitochondrial antiviral signaling protein
• NCBI Official Symbol: MAVS
• NCBI Official Synonym Symbols: IPS1; VISA; IPS-1; CARDIF
• NCBI Protein Information: mitochondrial antiviral-signaling protein
• UniProt Protein Name: Mitochondrial antiviral-signaling protein
• Protein Family: Mitochondrial antiviral-signaling protein
• UniProt Gene Name: MAVS
• UniProt Synonym Gene Names: IPS1; KIAA1271; VISA; MAVS; Cardif; IPS-1; VISA
• UniProt Entry Name: MAVS_HUMAN

NCBI Description

This gene encodes an intermediary protein necessary in the virus-triggered beta interferon signaling pathways. It is required for activation of transcription factors which regulate expression of beta interferon and contributes to antiviral immunity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]

Uniprot Description

MAVS: Required for innate immune defense against viruses. Acts downstream of DDX58/RIG-I and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFN-beta and RANTES (CCL5). May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis. Interacts with DDX58/RIG-I, IFIH1/MDA5, TRAF2 and TRAF6. May interact with IRF3, FADD, RIPK1, CHUK and IKBKB. Does not interact with TBK1. Interacts with and is cleaved by HCV and hepatitis GB virus B NS3/4A proteases. Interacts with and is cleaved by HHAV protein 3ABC. Interacts with NLRX1. Interaction with NLRX1 requires the CARD domain. Interacts with PSMA7. Interacts with TRAFD1. Interacts (via C-terminus) with PCBP2 in a complex containing MAVS/IPS1, PCBP2 and ITCH. Interacts with CYLD. Interacts with SRC. Interacts with DHX58/LGP2 and IKBKE. Present in T-cells, monocytes, epithelial cells and hepatocytes. Ubiquitously expressed, with highest levels in heart, skeletal muscle, liver, placenta and peripheral blood leukocytes. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Adaptor/scaffold; Membrane protein, integral

Chromosomal Location of Human Ortholog: 20p13

Cellular Component: peroxisomal membrane; mitochondrial outer membrane; mitochondrion; mitochondrial membrane; integral to membrane

Molecular Function: protein binding; signal transducer activity; CARD domain binding; protein kinase binding

Biological Process: positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of protein import into nucleus, translocation; viral reproduction; positive regulation of tumor necrosis factor production; signal transduction; positive regulation of interleukin-8 production; negative regulation of viral genome replication; defense response to bacterium; positive regulation of transcription factor import into nucleus; positive regulation of interferon-beta production; innate immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; positive regulation of protein amino acid phosphorylation; positive regulation of defense response to virus by host; negative regulation of interferon type I production; activation of innate immune response; defense response to virus; positive regulation of interferon-alpha production